7SSV image
Entry Detail
PDB ID:
7SSV
EMDB ID:
Keywords:
Title:
Structure of human Kv1.3 with Fab-ShK fusion
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2021-11-11
Release Date:
2022-06-29
Method Details:
Experimental Method:
Resolution:
3.39 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Potassium voltage-gated channel subfamily A member 3,Green fluorescent protein fusion
Chain IDs:A, B, C, D
Chain Length:856
Number of Molecules:4
Biological Source:Homo sapiens, Aequorea victoria
Polymer Type:polypeptide(L)
Description:Fab-ShK fusion, heavy chain
Chain IDs:E (auth: H)
Chain Length:270
Number of Molecules:1
Biological Source:unidentified
Polymer Type:polypeptide(L)
Description:Fab-ShK fusion, light chain
Chain IDs:F (auth: L)
Chain Length:216
Number of Molecules:1
Biological Source:unidentified
Primary Citation
Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators.
Nat Commun 13 3854 3854 (2022)
PMID: 35788586 DOI: 10.1038/s41467-022-31285-5

Abstact

The Kv1.3 potassium channel is expressed abundantly on activated T cells and mediates the cellular immune response. This role has made the channel a target for therapeutic immunomodulation to block its activity and suppress T cell activation. Here, we report structures of human Kv1.3 alone, with a nanobody inhibitor, and with an antibody-toxin fusion blocker. Rather than block the channel directly, four copies of the nanobody bind the tetramer's voltage sensing domains and the pore domain to induce an inactive pore conformation. In contrast, the antibody-toxin fusion docks its toxin domain at the extracellular mouth of the channel to insert a critical lysine into the pore. The lysine stabilizes an active conformation of the pore yet blocks ion permeation. This study visualizes Kv1.3 pore dynamics, defines two distinct mechanisms to suppress Kv1.3 channel activity with exogenous inhibitors, and provides a framework to aid development of emerging T cell immunotherapies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures